The article as written is making strong claims about a population it doesn't define very well...
Sorry to hear about the short tail running in the family.
>Fructose enhances liver/body weight ratio and kidney weight; soybean oil is protective in spleen and kidney.
From the caption on fig 2.
>To our surprise, we found that at 20 weeks the F-HFD did not cause diabetes (fasting blood glucose level > 200 mg/dL) whereas the SO-HFD did (Fig 4A).
This is in the results section as well under what I hope is just the heading and not an actual conclusion they drew: "Soybean oil induces diabetes, glucose intolerance and insulin resistance (IR)"
That's enough to give me some serious pause. If anyone has an explanation for why they felt comfortable claiming such certainty from the trial, I'd love to be wrong about this. It looks like you could just as easily claim that coconut oil prevents these things from the data provided.
I also am curious where the fructose + soybean oil + high fat diet group went when they started doing genetic analysis. They just disappear. Maybe I missed it, but it doesn't seem to be addressed in materials and methods or in the conclusions.
As a lay-person, when I come to this article, I have no idea of the information in the study. Which is why the veneer of a scientific study on this makes it actively worse for me to trust. And then if I ever find out the study is wrong, I trust science less, because I put my bets on a finding that was basically a coin-flip conclusion.
Now, I'm not inclined to trust the scientific process less because it finds something is wrong, but I also don't think I'm the average internet person.
This is a classic N=1 study of one sex and one genome of mouse. As such this work is of almost no know relevance to other strains of mice, let alone to humanity.
If you want an example of how mice dietary studies should be done then look to the National Institute on Aging and its Interventions Testing Program. They use both sexes and mice that are as genetically diverse as humanity.
N-of-1 studies should be deprecated by journals and by NIH. Embrace diversity before making broad translational claims.